



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 9, 2021

Mark Rothera  
Chief Executive Officer  
Silence Therapeutics plc  
72 Hammersmith Road  
London W14 8TH  
United Kingdom

**Re: Silence Therapeutics plc**  
**Registration Statement on Form F-1**  
**Filed March 9, 2021**  
**File No. 333-254021**

Dear Mr. Rothera:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact David Gessert at 202-551-2326 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences